Russell W. Jenkins, MD, Ph.D., a physician investigator in the Krantz Family Center for Cancer Research at the Mass General ...

Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer. Invikafusp alfa ...

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism ...

Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...

Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025IND applications for initiating first-in-human studies for ZW20 ...

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...

The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...

Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage ...

Janux Therapeutics has a robust balance sheet, with $658.1 million in liquid assets and no debt. See why I reiterate my buy ...

Adcentrx begins patient dosing in phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 to treat advanced solid tumours: San Diego, California Wednesday, ...